Offer for Cambridge Antibody

AstraZeneca PLC
30 June 2006



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR
FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE
RELEVANT LAWS OF SUCH JURISDICTION

                                                           FOR IMMEDIATE RELEASE
                                                                    30 June 2006


                             Recommended Cash Offer
                           by AstraZeneca UK Limited
                                      for
                    Cambridge Antibody Technology Group plc
                          Initial Offer Period Closed
                       Subsequent Offer Period Commenced

Summary
     
•    On 22 June 2006, AstraZeneca declared the Offer for CAT wholly 
     unconditional and extended the Initial Offer Period until 29 June 2006.

•    AstraZeneca now announces that it has acquired, or received valid 
     acceptances of the Offer in respect of, 41,262,279 CAT Shares (including 
     CAT Shares underlying CAT ADSs) in aggregate, representing approximately 
     95.95 per cent. of the CAT Shares (including CAT Shares underlying CAT 
     ADSs) to which the Offer relates.

•    Accordingly, AstraZeneca intends to apply for the delisting of CAT Shares 
     and CAT ADSs and to commence the compulsory acquisition of the remaining 
     CAT Shares (including CAT Shares underlying CAT ADSs).

•    AstraZeneca also announces the commencement of the Subsequent Offer Period, 
     which is expected to remain open for acceptance until such time as the 
     compulsory acquisition procedures are completed or until 3.00pm (London
     time), 10.00am (New York City time) on 22 September 2006, whichever occurs
     earlier.

•    Settlement of all acceptances (including in respect of CAT ADSs) received 
     complete in all respects by 22 June 2006 and not withdrawn before 29 June 
     2006 will occur by 6 July 2006.  Settlement of all acceptances received
     complete in all respects after 22 June 2006 will occur within 14 calendar 
     days of such receipt.

•    Holders of CAT Shares who have not already accepted the Offer are urged to 
     do so as soon as possible by following the procedures set out in the Offer 
     Document.

Acceptances

As at 3.00pm (London time), 10.00am (New York City time) on 29 June 2006, valid
acceptances of the Offer had been received in respect of 35,562,279 CAT Shares
(including CAT Shares represented by 2,085,549 CAT ADSs), representing
approximately 82.70 per cent. of the CAT Shares to which the Offer relates.
None of these acceptances were received from persons acting in concert with
AstraZeneca.  Of these valid acceptances, valid elections for the Loan Note
Alternative had been received in respect of a total of 512,743 CAT Shares.
Including the 5,700,000 CAT Shares acquired by AstraZeneca since 23 May 2006,
AstraZeneca has acquired, or received valid acceptances of the Offer in respect
of, 41,262,279 CAT Shares (including CAT Shares represented by 2,085,549 CAT
ADSs) in aggregate, representing approximately 95.95 per cent. of the CAT Shares
to which the Offer relates.

For the purposes of this announcement, the number of CAT Shares (including those
represented by CAT ADRs) to which the Offer relates is 43,002,698, being the
53,220,681 shares in issue as of the date of this announcement less the
10,217,983 shares held by AstraZeneca prior to the commencement of the Offer
Period.

Including the 10,217,983 CAT Shares held by AstraZeneca prior to the
commencement of the Offer Period, AstraZeneca has acquired, or received valid
acceptances of the Offer in respect of, 51,480,262 CAT Shares (including CAT
Shares represented by 2,085,549 CAT ADSs) in aggregate, representing 96.73 per
cent. of the existing issued share capital of CAT.

In addition to CAT ADSs tendered prior to 3.00pm (London time), 10.00am (New
York City time), on 29 June 2006, 30,814 ADSs are subject to notice of
guaranteed delivery period.

The Offer was declared unconditional in all respects on 22 June 2006.
AstraZeneca announces that the Initial Offer Period, which was extended until 29
June, is now closed for acceptance and the withdrawal rights of persons that
have tendered their securities will be terminated.

Prior to the announcement of the Offer, AstraZeneca had received irrevocable
undertakings to accept the Offer in respect of 190,569 CAT Shares in aggregate,
representing approximately 0.36 per cent. of the existing issued share capital
of CAT.  Valid acceptances have been received in respect of all of these CAT
Shares and such acceptances are included in the total referred to above.

As at the date of this announcement, affiliates of Goldman Sachs International
and Deutsche Bank (who are acting in concert (within the meaning of the City
Code) with AstraZeneca) held 78,084 CAT Shares in aggregate, representing 0.15
per cent. of the existing issued share capital of CAT.

Commencement of Subsequent Offer Period and Settlement

AstraZeneca also announces the commencement of the Subsequent Offer Period,
which is expected to remain open for acceptance until such time as the
compulsory acquisition procedures referred to in part II of the Offer Document
are completed or until 3.00pm (London time), 10.00am (New York City time) on 22
September 2006, whichever occurs earlier.  If CAT Securities are tendered into
the Offer during the Subsequent Offer Period, such holders will not have the
ability to withdraw their tender of such securities, subject to certain
conditions set out in the Offer Document.  If the CAT Securities are acquired
pursuant to compulsory acquisition procedures described below, no withdrawal
rights will exist in respect of the securities so acquired.

To the extent they have not already done so, holders of CAT Shares and CAT ADSs
who hold such securities in certificated form who have not yet accepted the
Offer but wish to do so should complete and return their Form of Acceptance and
Letter of Transmittal as soon as possible in accordance with the instructions
set out in the Offer Document and in the Form of Acceptance and Letter of
Transmittal.  The CAT Shareholders and ADS holders who hold their CAT Shares in
uncertificated or book-entry form and who have not yet accepted the Offer but
wish to do so are reminded to take the necessary steps through CREST or their
respective Agent Institution (as applicable) as soon as possible.

Settlement of the consideration to accepting CAT Shareholders and accepting
holders of CAT ADSs (including holders of CAT ADSs that deliver a Notice of
Guaranteed Delivery in a timely manner) or their designated agents will be
effected as set out below:

(a)  in the case of acceptances received complete in all respects by 22 June 
     2006 and not withdrawn before today, within 14 calendar days of such
     date; or

(b)  in the case of acceptances received complete in all respects after 22 June 
     2006 but while the Offer remains open for acceptance, within 14 calendar 
     days of such receipt.

De-listing and Compulsory Acquisition

As AstraZeneca has attained the required 75 per cent. of the voting rights
attaching to CAT Shares, AstraZeneca is taking steps to procure the application
by CAT for the cancellation of the listing of CAT Shares from the Official List
and the cancellation of trading in CAT Shares on the London Stock Exchange's
market for listed securities. It is anticipated that cancellation of listing and
trading will take effect no earlier than 28 July 2006. AstraZeneca also intends
to procure that CAT apply for de-listing of the CAT ADSs from NASDAQ.  Such
de-listings would significantly reduce the liquidity and marketability of any
CAT Shares or CAT ADSs that are not acquired by AstraZeneca.  AstraZeneca will
also request that CAT terminate the existing deposit agreement through which the
ADS programme is operated. In addition, if the number of holders of CAT
Securities in the United States falls below 300 (calculated in accordance with
Rule 12g3-2(a) under the Exchange Act), AstraZeneca intends to procure that CAT
file a Form 15 with the SEC to request that its registration under the Exchange
Act be terminated or suspended. It is also anticipated that, after such
cancellations, CAT will be re-registered as a private company under the relevant
provisions of the Companies Act.

Given that AstraZeneca has received acceptances under the Offer in respect of,
or otherwise acquired, more than 90 per cent. of CAT Shares to which the Offer
relates, AstraZeneca intends to exercise its rights pursuant to the provisions
of Schedule 2 of the Interim Regulations to acquire compulsorily, on the same
terms as the Offer, the remaining CAT Shares (including shares underlying CAT
ADSs) in respect of which the Offer has not been accepted.

Defined terms used in this announcement have the same meanings as in the Offer
Document dated 23 May 2006.

Enquiries:

AstraZeneca

Media Enquiries:

Steve Brown (London)                                 [phone]
Edel McCaffrey (London)                              [phone]
Staffan Ternby (Sweden)                              [phone]

Analyst/Investor Enquiries:
Jonathan Hunt (London)                               [phone]
Mina Blair (London)                                  [phone]
Ed Seage (US)                                        [phone]
Jorgen Winroth (US)                                  [phone]

Goldman Sachs International                          [phone]
Guy Slimmon
Mark Sorrell


This announcement is for informational purposes only and does not constitute an
offer to sell or an invitation to purchase any securities or the solicitation of
an offer to buy any securities, pursuant to the Offer or otherwise. This
announcement also does not constitute a Solicitation / Recommendation Statement
under the rules and regulations of the US Securities and Exchange Commission
(the 'SEC'). The Offer is being made solely by means of the Offer Document and
the Form of Acceptance accompanying the Offer Document, which contain the full
terms and conditions of the Offer, including details of how the Offer may be
accepted.  In the United States, AstraZeneca has filed a Tender Offer Statement
containing the Offer Document and other related documentation with the SEC on
Schedule TO and CAT has filed a Solicitation/Recommendation Statement with the
SEC on Schedule 14D-9.  Free copies of the Schedule TO, the Schedule 14D-9 and
the other related documents filed by AstraZeneca or CAT in connection with this
Offer are available on the SEC's website at http://www.sec.gov.  The Offer
Document and Acceptance Forms accompanying the Offer Document have been made
available to all CAT Shareholders at no charge to them.  CAT Shareholders are
advised to read the Offer Document and the accompanying Acceptance Forms as they
contain important information.  CAT Shareholders in the United States are also
advised to read the Tender Offer Statement and the Solicitation/Recommendation
Statement as they contain important information.

Goldman Sachs International, which is authorised and regulated by the Financial
Services Authority, is acting exclusively for AstraZeneca and no one else in
connection with the Offer and will not be responsible to anyone other than
AstraZeneca for providing the protections afforded to clients of Goldman Sachs
International or for providing advice in relation to the Offer or any other
matters referred to in this announcement.

The availability of the Offer to CAT Shareholders who are not resident in and
citizens of the United Kingdom or the United States may be affected by the laws
of the relevant jurisdictions in which they are located or of which they are
citizens.  Such persons should inform themselves of, and observe, any applicable
legal or regulatory requirements of their jurisdictions.  Further details in
relation to overseas shareholders are contained in the Offer Document.

The Loan Notes which will be issued pursuant to the Loan Note Alternative have
not been, and will not be, listed on any stock exchange and have not been, and
will not be, registered under the Securities Act or under any relevant laws of
any state or other jurisdiction of the United States, nor have clearances been,
nor will they be, obtained from the securities commission or similar authority
of any province or territory of Canada and no prospectus has been, or will be,
filed, or registration made, under any securities law of any province or
territory of Canada, nor has a prospectus in relation to the Loan Notes been,
nor will one be, lodged with, or registered by, the Australian Securities and
Investments Commission, nor have any steps been taken, nor will any steps be
taken, to enable the Loan Notes to be offered in compliance with applicable
securities laws of Japan. Accordingly, unless an exemption under relevant
securities laws is available, the Loan Notes may not be offered, sold, re-sold
or delivered, directly or indirectly, in, into or from the United States or any
other Loan Note Restricted Jurisdiction in which an offer of Loan Notes would
constitute a violation of relevant laws or require registration of the Loan
Notes, or to or for the account or benefit of any US person or resident of any
other Loan Note Restricted Jurisdiction.

Unless otherwise determined by AstraZeneca and permitted by applicable law and
regulation, subject to certain exemptions, the Offer will not be capable of
acceptance from or within a Restricted Jurisdiction. Accordingly, copies of this
announcement must not be, directly or indirectly, mailed or otherwise forwarded,
distributed or sent in, into or from a Restricted Jurisdiction and persons
receiving this announcement (including custodians, nominees and trustees) should
observe these restrictions and must not mail or otherwise distribute this
announcement in, into or from any such jurisdictions.
--------------------------


                      This information is provided by RNS
            The company news service from the London Stock Exchange